Abstract
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm 3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm 3 (20-122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log 2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.
【초록키워드】 mRNA vaccine, mRNA-1273, CD4, SARS-CoV-2 vaccine, BNT162b2, Humoral response, AIDS, ART, age, PLWH, Heterologous, Cell-mediated immunity, IFN-γ, microneutralization, Combination, dose, anti-RBD, immune dysregulation, Support, Side-effect, second dose, advanced disease, log, receiving, median, recorded, with HIV, generally mild, 【제목키워드】 COVID-19, immunogenicity, mRNA vaccine, dose, with HIV,